Cerevel Therapeutics Holdings, Inc. (CERE)

CERE Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	322.4	418.43	138.39	197.22	387.82	83.68
Short-Term Investments	525.86	574.5	755.51	372.67	0	0
Cash & Cash Equivalents	848.25	992.93	893.9	569.89	387.82	83.68
Cash Growth	2.34%	11.08%	56.85%	46.95%	363.45%	-
Other Current Assets	11.32	14.01	11.75	8.13	2.74	3.4
Total Current Assets	859.58	1,007	905.65	578.02	390.56	87.08
Property, Plant & Equipment	44.6	45.77	49.29	51.7	48.62	27.49
Long-Term Investments	218.59	185.2	58.13	52.27	0	0
Other Long-Term Assets	4.58	5.39	4.76	6.93	6.09	6.24
Total Long-Term Assets	267.77	236.36	112.17	110.9	54.71	33.73
Total Assets	1,127	1,243	1,018	688.92	445.27	120.81
Accounts Payable	10.84	11.86	10.06	11.3	4.99	2.11
Current Debt	3.52	3.4	2.9	2.44	2.04	2.59
Other Current Liabilities	69.75	76.91	59.6	28.8	22.52	10.18
Total Current Liabilities	84.1	92.18	72.56	42.54	29.55	14.88
Long-Term Debt	478.78	477.37	424.02	67.65	30.97	25.82
Other Long-Term Liabilities	0	0	0	0	0.24	2.29
Total Long-Term Liabilities	478.78	477.37	424.02	67.65	31.21	28.11
Total Liabilities	562.89	569.55	496.58	110.19	60.75	42.98
Total Debt	482.3	480.78	426.92	70.09	33.01	28.41
Debt Growth	9.94%	12.62%	509.13%	112.35%	16.17%	-
Retained Earnings	-1,532.51	-1,400.6	-967.76	-616.24	-390.91	-244.3
Comprehensive Income	-1.09	1.77	3.1	-0.99	0	0
Shareholders' Equity	564.46	673.75	521.24	578.73	384.52	77.82
Net Cash / Debt	365.96	512.15	466.98	499.8	354.82	55.27
Net Cash / Debt Growth	-6.20%	9.67%	-6.57%	40.86%	541.96%	-
Net Cash Per Share	2.02	3.16	3.09	3.66	4.82	1.25
Working Capital	775.47	914.76	833.09	535.48	361.01	72.2
Book Value Per Share	3.11	4.16	3.45	4.24	5.22	1.76

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).